SCHEMBL29943503

SCHEMBL29943503

Nc1ccccc1-c1cccnn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
IDO1 P14902 4/20 0.44
KDM4E B2RXH2 3/20 0.42
NPC1 O15118 3/20 0.42
GAA P10253 3/20 0.42
HSD17B10 Q99714 2/20 0.42
ATAD2 Q6PL18 1/20 0.40
HDAC4 P56524 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
RAB9A P51151 2/20 0.38
HTR2C P28335 2/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
GOT1 P17174 1/20 0.38
HPGD P15428 1/20 0.37
CYP3A4 P08684 1/20 0.36
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3102409 1.00 ALDH1A1 (0.54) ALDH1A1L3MBTL1IDO1KDM4ENPC1
SCHEMBL6017122 0.78 ALDH1A1 (0.52) ALDH1A1L3MBTL1IDO1KDM4ENPC1
SCHEMBL3322710 0.76 HDAC4 (0.38) ALDH1A1L3MBTL1KDM4EHSD17B10HDAC4
SCHEMBL3704382 0.75 HTR2C (0.38) GAAHDAC4HTR2CMEN1KMT2A
SCHEMBL34461976 0.75 GABRG2 (0.47) ALDH1A1L3MBTL1IDO1KDM4ENPC1
SCHEMBL8138036 0.75 IDO1 (0.44) ALDH1A1IDO1HSD17B10SMN1; SMN2RAB9A
SCHEMBL30717913 0.75 IDO1 (0.44) ALDH1A1IDO1HSD17B10SMN1; SMN2RAB9A
SCHEMBL8893831 0.75 LMNA (0.48) ALDH1A1IDO1KDM4ENPC1GAA
SCHEMBL3464878 0.75 NPC1 (0.45) ALDH1A1L3MBTL1IDO1KDM4ENPC1
SCHEMBL29942556 0.75 IDO1 (0.44) ALDH1A1IDO1HSD17B10SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4051674-A1 BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2022-09-07 EP disclosed